BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and invest...
Bonus Content - Trends in Global Biopharma Deals: Lazard’s Kingston and Raine
With most of the highly attractive late-stage assets already scooped up, pharmas are turning their sights to Phase II companies, and lining up their case to make an attractive offer and move fast. About 40% of the M&A deals in 2023-24 were completed in less than six weeks, from approach to announcement, according to Lazard’s data. Michael Kingston and Dale Raine, global co-heads of biopharma at Lazard, joined The BioCentury Show this week to discuss the M&A outlook amid the still-precarious biotech financing landscape.The BioCentury Show, featuring BioCentury one-on-one with an industry KOL, is available on Apple, Spotify and wherever you listen to your favorite podcasts and in video podcast format on BioCentury’s YouTube channel.View full story: https://www.biocentury.com/article/65385800:00 - Introduction03:01 - Capital Markets Outlook06:01 - M&A15:19 - Breaking Down Deals24:29 - AsiaTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text
--------
34:54
Ep. 269 - Trends in VC Funds, Obesity Start-ups and More
Lately, it appears some biotech VCs have hit a ceiling, capping their new funds at or below the amount of their previous vehicles, says Paul Bonanos on the latest BioCentury This Week. Bonanos and his BioCentury editorial colleagues discuss what’s behind the trend as they assess VC fundraising in this post-‘supercycle’ era. The editors also evaluate the state of play for venture-backed obesity plays and which VCs are active in the space, as well as takeaways from the latest BioCentury Show podcast featuring Aoife Brennan, CEO of Climb Bio. Finally, the team features the new book from long-time biotech executive and current SV Health Investors partner Tim Harris, In Pursuit of Unicorns: A Journey through 50 Years of Biotechnology.View full story: https://www.biocentury.com/article/65448800:00 - Introduction02:08 - Trends in VC Funds12:16 - Obesity Start-ups19:46 - The BioCentury Show with Aoife Brennan26:50 - Tim Harris' New Book: In Pursuit of UnicornsTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text
A pair of lawmakers have dealt the Biosecure Act a setback that could derail the legislation, even as Congress continues its push to reduce reliance on China in the life sciences. On the latest BioCentury This Week podcast, Washington Editor Steve Usdin explains why Sen. Rand Paul (R-Ky.) and Rep. Jamie Raskin (D-Md.) refused to sign off on inclusion of the anti-China biotech bill in the must-pass National Defense Authorization Act, what provisions the defense bill has that seek to enhance U.S. biotech supply chain resilience and whether Biosecure can be resurrected. And in the latest in neurology, Executive Editor Selina Koch discusses Novartis and PTC's $1 billion deal for the biotech’s Huntington disease therapy, and how several biotechs are poised to take therapies against the long undruggable KCC2 to the clinic for neurological disorders. Heads up: BioCentury’s JPM Guide 2025 is out now.View full story: https://www.biocentury.com/article/65442000:00 - Introduction01:42 - Biosecure Setback10:01 - Novartis' $1B PTC Deal 16:28 - KCC2 ActivationTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text
--------
21:49
Ep. 267 - Trump's NIH Pick & Multi-targeted CAR Ts
On the latest BioCentury This Week podcast, Washington Editor Steve Usdin and colleagues discuss how President-elect Donald Trump’s pick to lead NIH, Jay Bhattacharya, would lead NIH and how that could affect the biopharma industry.The BioCentury team then discusses its analysis of abstracts released ahead of the American Society of Hematology (ASH) and Society for Immunotherapy of Cancer (SITC) annual conferences, highlighting methods for applying dual or bispecific CAR T cell designs to solid tumors. And they also analyze FDA approvals of products by biotech companies, noting that current trends show biotechs shedding their reliance on pharma to get drugs across the finish line for approval.View full story: https://www.biocentury.com/article/65436300:00 - Introduction01:08 - Trump's NIH Pick12:13 - Multi-targeted CAR Ts19:26 - Biotech FDA ApprovalsTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text
--------
27:26
Ep. 266 - Jefferies Recap, FDA Commissioner & Biosecure Update
Positive vibes about biotech emanating from the Jefferies Healthcare Conference were overshadowed by the uncertainty that is ahead because of the result of the U.S. elections. On the latest BioCentury This Week, BioCentury’s editors discuss how the unconventional cabinet nominations of the incoming Trump administration have cast a pall over what had been growing enthusiasm for the prospects of the biotech sector. Washington Editor Steve Usdin also discusses what the nomination of Marty Makary as the next FDA Commissioner could mean for the sector, and recaps the latest update on the Biosecure Act. The BioCentury editors also discuss which pharmas are in or out in making a challenge to Eli Lilly and Novo Nordisk in the obesity market.View full story: https://www.biocentury.com/article/65431900:00 - Introduction00:32 - Jefferies Conference Takeaways06:25 - Trump Nominations17:41 - Biosecure Act Update21:01 - Pharma in ObesityTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text
BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.
USA